<p>The G protein-coupled receptors (GPCRs) are important targets in drug discovery. In several cases, the endogenous ligands that activate the GPCRs of pharmaceutical interest are peptides. Unfortunately, peptides are in general not suitable as drugs, since the peptide structure is associated with several disadvantages, such as low oral bioavailability, rapid degradation and low receptor subtype selectivity. Thus, there is a strong need for drug-like nonpeptide ligands to peptide-activated GPCRs. However, to discover nonpeptide ligands that mimic the effect of the endogenous peptide, i.e. peptidomimetics, is a tremendous challenge. In fact, morphine and the related opioids were the only known examples of peptidomimetics before 1995 and these ligands were known long before the native endogenous peptide ligands were discovered. </p><p>The main objective of the work described in this thesis was to design, synthesize and biologically evaluate selective nonpeptide agonists to the peptide-activated GPCR AT₂. The AT₂ receptor belongs to the renin–angiotensin system, where the octapeptide angiotensin II (Ang II) is the major effector peptide. Ang II mediates its effects through the two GPCRs AT₁ and AT₂. The AT₁ receptor is already an established target in the treatment of hypertension. The physiological role of the AT₂ receptor, which is up-regulated in certain pathological conditions, is not fully understood but it seems to include positive effects such as vasodilatation, tissue repair, tissue regeneration and neuronal differentiation. </p><p>In the current investigation we started from the nonpeptide and nonselective (AT₁/ AT₂) compound L-162,313. This ligand is a known AT₁ receptor agonist but its effect on the AT₂ receptor was unknown at the start of this project. We were able to show that it acts as an agonist also at the AT₂ receptor. Furthermore, stepwise synthetic modifications of L-162,313 led to the identification of the first selective nonpeptide AT₂ receptor agonist. Following the discovery of this compound several selective nonpeptide AT₂ receptor agonists were identified. It was also revealed that a minor structural alteration of one of these compounds interconverted the functional activity from agonism to antagonism. The structural requirement for agonism vs antagonism was therefore studied. The functionality switch was suggested, at least partly, to be due to the spatial relationship between the methyleneimidazole group and the isobutyl side chain of the compounds. To further investigate the bioactive conformation(s) of this series of compounds enantiomerically pure analogues with conformationally constrained isobutyl chains were prepared. This study revealed that the direction of the isobutyl side chain determine whether the compounds act as agonists or antagonists at the AT₂ receptor. Further investigations are required to fully elucidate the bioactive conformation(s) of these nonpeptide AT₂ receptor agonists.</p><p>We believe that the selective nonpeptide AT₂ receptor agonists and antagonists identified in this thesis will serve as important research tools in the continuing investigation of the physiological role of the AT₂ receptor. We also believe that these drug-like compounds might provide potential leads in drug discovery processes.</p>

The G protein-coupled receptors (GPCRs) are important targets in drug discovery. In several cases, the endogenous ligands that activate the GPCRs of pharmaceutical interest are peptides. Unfortunately, peptides are in general not suitable as drugs, since the peptide structure is associated with several disadvantages, such as low oral bioavailability, rapid degradation and low receptor subtype selectivity. Thus, there is a strong need for drug-like nonpeptide ligands to peptide-activated GPCRs. However, to discover nonpeptide ligands that mimic the effect of the endogenous peptide, i.e. peptidomimetics, is a tremendous challenge. In fact, morphine and the related opioids were the only known examples of peptidomimetics before 1995 and these ligands were known long before the native endogenous peptide ligands were discovered. The main objective of the work described in this thesis was to design, synthesize and biologically evaluate selective nonpeptide agonists to the peptide-activated GPCR AT2. The AT2 receptor belongs to the renin–angiotensin system, where the octapeptide angiotensin II (Ang II) is the major effector peptide. Ang II mediates its effects through the two GPCRs AT1 and AT2. The AT1 receptor is already an established target in the treatment of hypertension. The physiological role of the AT2 receptor, which is up-regulated in certain pathological conditions, is not fully understood but it seems to include positive effects such as vasodilatation, tissue repair, tissue regeneration and neuronal differentiation. In the current investigation we started from the nonpeptide and nonselective (AT1/ AT2) compound L-162,313. This ligand is a known AT1 receptor agonist but its effect on the AT2 receptor was unknown at the start of this project. We were able to show that it acts as an agonist also at the AT2 receptor. Furthermore, stepwise synthetic modifications of L-162,313 led to the identification of the first selective nonpeptide AT2 receptor agonist. Following the discovery of this compound several selective nonpeptide AT2 receptor agonists were identified. It was also revealed that a minor structural alteration of one of these compounds interconverted the functional activity from agonism to antagonism. The structural requirement for agonism vs antagonism was therefore studied. The functionality switch was suggested, at least partly, to be due to the spatial relationship between the methyleneimidazole group and the isobutyl side chain of the compounds. To further investigate the bioactive conformation(s) of this series of compounds enantiomerically pure analogues with conformationally constrained isobutyl chains were prepared. This study revealed that the direction of the isobutyl side chain determine whether the compounds act as agonists or antagonists at the AT2 receptor. Further investigations are required to fully elucidate the bioactive conformation(s) of these nonpeptide AT2 receptor agonists. We believe that the selective nonpeptide AT2 receptor agonists and antagonists identified in this thesis will serve as important research tools in the continuing investigation of the physiological role of the AT2 receptor. We also believe that these drug-like compounds might provide potential leads in drug discovery processes.

Patients suffering from hypertension often develop non-Insulin dependent diabetes mellitus (NIDDM), a condition caused by Insulin resistance. Though these patients have normal Insulin receptor (IR) and high levels of Insulin in blood, they fail to have IR-mediated signaling essential for glucose uptake and availability. NIDDM usually begins as insulin resistance, a condition in which Insulin Receptor (IR)-mediated signaling that leads to glucose uptake and glucose availability to cells is inhibited even in the presence of high levels of Insulin in blood. Mechanisms for the development of this Insulin resistance in patients suffering from hypertension are unclear. Angiotensin II (Ang II) hormone has been implicated in the pathogenesis of insulin resistance and inhibitors of Ang II receptor AT1 are shown to improve insulin sensitivity. Here we show that in the skeletal muscle tissue of SHR rats, Insulin Receptor (IR) beta- subunit forms a complex with the AT1 receptor and co-immunoprecipitates with IR-beta. Such strong AT1-IR association was not observed in normo-tensive rat tissue. To our knowledge this is the first report that shows AT1 can associate with IR-beta in mammalian tissue and that such association might play a role in the regulation of signaling by IR-beta. We further demonstrate that a 2-hour pre-incubation with Ang II (at concentrations 50pM to 1?ÝM) significantly inhibits 125I-insulin binding to IR in human cell line MCF-7. This effect was not seen when Ang II exposure was performed for shorter periods. The two-hour exposure to Ang II also led to the formation of a protein complex containing AT1 and IR-beta, similar to that seen in skeletal muscle tissue of SHR rats. Both AT1-IR association and differential tyrosine phosphorylation of IR-beta and associated proteins were inhibited when the cells were pre-treated with the AT1 antagonist losartan. These observations suggest that continuous presence of Ang II would result in sequestering IR in the AT1-IR complex and prevent IR from binding insulin. It also coincided with differential tyrosine-phosphorylation of IR beta-subunit and associated proteins, than that generated when IR was activated by insulin. Therefore, we infer that conformational alterations in IR caused by AT1-IR-beta association underlie the development of Ang II-induced insulin resistance. Based on these data we propose a model for AT1-mediated insulin resistance that involves receptor level interaction between the AT1 and the IR. Therefore, Insulin-independent, Ang II-induced tyrosine phosphorylation of IR prevents IR from binding Insulin and contributes to Insulin resistance. The observation that drugs that inhibit Angiotensin II converting enzyme (ACE), or activation of AT1 receptor, not only reduce hypertension, but also induce insulin sensitivity further supports the role for Ang II and AT1 in the development of NIDDM.

L'hormone angiotensine II (Ang II) possède deux principaux récepteurs, le récepteur AT1 (R-AT1) et le récepteur AT2 (R-AT2). Le R-AT1 est reconnu pour assurer la majorité des effets de l'Ang II, alors que les rôles et les mécanismes d'action du R-AT2 font l'objet de nombreux débats. Ces controverses peuvent être expliquées, d'une part par les nombreux modèles cellulaires ou animaux utilisés, de par son faible niveau d'expression et d'autre part par l'absence de ligand sélectif non-peptidique ciblant celui-ci. Dans le laboratoire, nous avons caractérisé un nouvel agoniste hautement sélectif pour le R-AT2 et non peptidique appelé le composé 21 (C21) ou M24. Grâce à ce composé, nous avons pu étudier une partie des rôles associés au R-AT2 dans la fonction adipocytaire. Tout d'abord, nous avons utilisé un modèle de cultures primaires de préadipocytes de rats pour étudier la différenciation des préadipocytes provenant de différents dépôts de tissus adipeux. Dans un deuxième temps, nous avons utilisé un modèle animal de résistance à l'insuline qui a été induit par une diète riche en gras et en fructose (HFHF). Les objectifs de mon projet étaient de déterminer 1) le rôle du R-AT2 sur l'adipogenèse et 2) l'effet de l'activation du R-AT2 dans un modèle de rats résistants à l'insuline. Nos résultats montrent que l'expression protéique du R-AT2 est plus importante en début de différenciation. Par ailleurs, l'activation du R-AT2, par le M24 (1 nM), augmente l'expression de PPAR[gamma]. De plus, l'activation du R-AT2 augmente l'accumulation de lipides dans les adipocytes sous-cutanés, mais pas dans les adipocytes rétropéritonéaux, tandis que le R-AT1 diminue l'accumulation de lipides dans les deux types cellulaires. Les résultats obtenus avec un shARN contre le R-AT2, dans ces mêmes cultures, indiquent que l'absence du R-AT2 empêche la différenciation des préadipocytes en adipocytes matures. D'autre part, chez les rats soumis à la diète HFHF, nos résultats montrent que le M24, ainsi que le losartan, préviennent la résistance à l'insuline. Par ailleurs, nous avons observé d'importants changements morphologiques dans les tissus adipeux après traitements au M24. En effet, le M24 diminue le nombre de gros adipocytes dans le tissu adipeux sous-cutané. Sachant que les nouveaux petits adipocytes sous-cutanés corrèlent avec une meilleure sensibilité à l'insuline, nos études suggèrent que le M24 améliore la sensibilité à l'insuline de nos animaux, principalement, en régulant la physiologie du tissu adipeux. Ensemble, mes résultats montrent que le R-AT2 joue un rôle important dans la physiologie des adipocytes et par conséquent du tissu adipeux. De plus, l'agoniste M24 ouvre la porte à de nouvelles études sur le R-AT2 pour étudier son potentiel thérapeutique dans les pathologies métaboliques telles que la résistance à l'insuline, le diabète de type 2 et l'obésité.

Plusieurs problèmes de santé peuvent être associés à un déséquilibre de l'homéostasie énergétique tels l'obésité, le diabète, les cancers et les maladies cardiovasculaires. Il est bien établi que l'angiotensine II (Ang II) joue un rôle dans le développement de ces pathologies. La plupart des effets néfastes de l'Ang II sont attribués au récepteur de type I (R-AT1) alors que l'activation du récepteur de type 2 (R-AT2) génère des effets qui s'opposent souvent à ceux du R-AT1. Des travaux suggèrent un rôle de l'Ang II dans la physiologie de l'adipocyte. Afin d'étudier l'implication du R-AT2 lors de l'adipogenèse dans des conditions normales et de perturbations de l'homéostasie, les cellules 3T3-L1 ont été choisies. Elles sont un modèle de différenciation adipocytaire utilisé depuis longtemps puisqu'elles possèdent les mêmes caractéristiques principales que les adipocytes et plusieurs résultats obtenus avec ce modèle ont été validés dans des modèles in vivo. Nos expériences de RT-PCR et d'études de liaison hormone-récepteur montrent que le R-AT2 n'est pas présent dans les préadipocytes, mais que son expression augmente au cours de la différenciation des cellules 3T3-L1. Nous avons utilisé un nouvel agoniste non-peptidique sélectif du R-AT2, le M24, afin d'éclaircir les rôles de ce récepteur lors de l'adipogenèse. L'activation du R-AT2 par le M24, en condition normale de différenciation, ne modifie pas l'expression des R-AT1 et R-AT2 ainsi que celle des marqueurs de la différenciation fonctionnelle tels aP2 et PPAR?. De plus, l'activation du R-AT2 n'affecte pas l'accumulation lipidique. Nous avons utilisé des traitements avec les acides gras, oléate et palmitate, afin de perturber l'homéostasie des cellules. Ces traitements n'ont pas modifié de manière significative les différents paramètres étudiés. Par conséquent, les effets bénéfiques potentiels de l'activation du R-AT2 par le M24, notamment sur la différenciation adipocytaire, n'ont pu être observés. D'autres études seront donc nécessaires afin d'éclaircir l'implication du R-AT2 lors de la différenciation adipocytaire des cellules 3T3-L1 et son effet bénéfique potentiel en condition de désordres métaboliques. Les causes possibles de cette absence d'effet sont discutées.

Sandra Pavlíčková Physiological effects mediated by the brain angiotensin receptors Diploma thesis Charles University in Prague, Faculty of Pharmacy in Hradec Králové Pharmacy Department of Biological and Medical Science Supervisor: Doc.MUDr. Josef Herink, DrSc. Renin-angiotensin system (RAS) is one of the oldest and the most important hormonal systems. "Classic" angiotensin system regulates the blood pressure and homeostasis of water and electrolytes. The main bioactive peptide of this system is angiotensin II (Ang II), which, according to recent research, does not affect only one organ. Installation of the so-called "tissue" RAS, which in many cases complements "systemic" Ang II system, changes the view on RAS. It was established, that RAS components are located on other non- typical places, which cannot be incorporated to the known endocrinal function of this system. Especially, discovery of angiotensin components and receptors in brain led to formation of new hypothesis and functional concepts about local effects of RAS, based on local synthesis of Ang II and angiotensin IV (Ang IV). Current studies found that physiological effects of the central angiotensin receptors can play an important role in neuroprotection and brain perfusion, can affect stress and behavioral disorders and influence...

Uma estreita relação entre a ação dos hormônios tireoidianos (HT) no sistema cardiovascular sendo mediada por componentes do sistema renina-angiotensina (SRA) tem sido descrita na literatura. Já foi demonstrado que o processo de isquemia/reperfusão (I/R) promove diminuição na expressão do receptor de angiotensina II do tipo 2 (AT2) no miocárdio, com consequente prejuízo funcional, enquanto o aumento de sua expressão melhorou a recuperação da função cardíaca. A hipótese do presente estudo é que o papel cardioprotetor exercido pelos HT ocorre com a participação do receptor AT2. Esta hipótese foi testada utilizando o modelo de I/R com a perfusão de coração isolado de camundongos selvagens e nocautes para o AT2, submetidos a tratamento por 14 dias com T3. Ainda foi avaliado o SRA mitocondrial, assim como o papel do óxido nítrico (NO) na recuperação pós-isquêmica. Os resultados apontam que a cardioproteção induzida pelo T3 é mediada pelo AT2, com consequente aumento na produção de NO e modulação de parâmetros do metabolismo mitocondrial. / Some authors have shown a close relationship between the action of thyroid hormone (TH) on cardiovascular system and renin angiotensin system (RAS) activation. Have been shown that ischemia/reperfusion (I/R) promotes decrease on angiotensin II type 2 receptor (AT2) expression in the myocardium, with functional worsening, on the other hand the AT2R increased improves the cardiac function after ischemia episodes. So, we have hypothesized that the cardioprotective effect of TH in I/R model may occur with the participation of AT2. This hypothesis was tested using I/R model in isolated hearts AT2 knockout and wild-type mice submitted to high levels of T3 by 14 days. The mitochondrial RAS was evaluated, as well as the nitric oxide (NO) role in post-ischemic recovery. The results show that TH induces cardioprotection through AT2 receptor, some mitochondrial metabolism parameters were modulated by TH and the NO production was increased.

Le Système Rénine Angiotensine tient une place prépondérante au sein de la circulation cérébrale. Les Antagonistes des Récepteurs AT1 à l'Angiotensine II (ARAII) ont prouvé leur efficacité dans la prévention de l'Accident Vasculaire Cérébral (AVC), indépendamment de leur effet anti-hypertenseur. Plusieurs mécanismes pourraient être impliqués dans cette cérébroprotection. D'une part, en bloquant les récepteurs AT1, les ARAII favorisent la stimulation des récepteurs AT2 à l'angiotensine II. Le caractère bénéfique lié à la stimulation des récepteurs AT2 s'oppose au caractère délétère lié à la stimulation des récepteurs AT1. Nous avons montré que cet équilibre AT1 - AT2 est modifié au niveau cérébrovasculaire suite à un régime hypersodé. En effet, la vasodilatation des artérioles cérébrales médiée par les récepteurs AT2 est abolie, ce qui pourrait constituer un élément délétère lors de la survenue d'un évènement ischémique. D'autre part, certains ARAII présentent une affinité pour les récepteurs PPAR-gamma. Cette activité, démontrée comme protectrice à différents niveaux vasculaires, pourrait également être bénéfique pour la circulation cérébrale. Nous avons en particulier montré que l'activation PPAR-gamma améliore les effets des ARAII au niveau de la circulation cérébrale (diamètre artériolaire, réactivité à l'angiotensine II). Les mécanismes en jeu semblent impliquer des modifications de la fonction des récepteurs AT1-AT2, indépendamment de leur expression. La stimulation des récepteurs AT2 et l'activation PPAR-gamma constituent donc deux propriétés particulières des ARAII. Ces propriétés pourraient participer au caractère cérébroprotecteur des ARAII, au-delà du seul blocage des récepteurs AT1. Le développement de molécules duales regroupant les activités antagoniste AT1 - agoniste PPAR-gamma pourrait constituer un avenir thérapeutique intéressant dans le traitement de l'hypertension en apportant une protection cérébrovasculaire supérieure aux traitements actuels / The Renin Angiotensin System plays a major role in cerebral circulation. AT1 receptor blockers (ARBs) afford protection against cerebrovascular complications that go beyond that to be expected from their blood pressure lowering action. Several mechanisms could explain such beneficial effects. Firstly, by blocking AT1 receptors, ARBs promote AT2 receptor stimulation by angiotensin II. The beneficial effect related to stimulation of AT2 receptors (vasodilation) counterbalances the deleterious actions of AT1 receptors stimulation. Changes in this ratio may then alter cerebral circulation. We demonstrated that the AT1- AT2 ratio is modified at the cerebrovascular level during high salt intake, which is a risk factor for stroke. The AT2-mediated vasodilation of pial arterioles is abolished. Secondly, some ARBs act as partial agonists of PPAR-gamma. Such an activity, which has been demonstrated to protect extracerebral vessels, could also be beneficial for cerebral circulation. Our results showed that PPAR-gamma activation improves ARB effects on cerebral circulation (arteriolar diameter, angiotensin II reactivity). The underlying mechanisms could imply functional regulation of AT1-AT2 receptors without any change in expression status. AT2 receptor stimulation and PPAR-gamma activity are two special properties of ARBs. These properties could contribute to the cerebroprotection induced by ARBs, beyond the AT1-receptor blockade. Development of new molecules with AT1-receptor blockade and PPAR-gamma activity could take part into the future therapeutic management of hypertension, providing a better cerebrovascular protection

In der vorliegenden Arbeit wurde der Einfluss der humanen AT2-Rezeptorexpression und -stimulation auf den Collagen I alpha 2-mRNA-Gehalt und die Migration von porcinen kardialen Fibroblasten untersucht, um die Frage zu klären, ob AT2-Rezeptoren in kultivierten kardialen Fibroblasten AT1-antagonistische antifibrotische und migrationshemmende Effekte auf den Collagen I alpha 2-mRNA-Gehalt bzw. die Migration ausüben. Um die Funktion der AT2-Rezeptoren in der Zellkultur untersuchen zu können, wurde die AT2-cDNA durch adenovirale Transduktion in die Fibroblasten übertragen und so der AT2-Rezeptor überexprimiert. Mittels RT-PCR wurden die relativen Änderungen im Collagen I alpha 2-mRNA-Gehalt in TGF-beta1- bzw. TGF-beta1 plus Ang II-stimulierten Fibroblasten im Vergleich zur unstimulierten Kontrolle bestimmt. Alle Werte wurden auf ein Referenzgen (beta-Actin) bezogen. Die AT2-Stimulation änderte den relativen Collagen I alpha 2-mRNA-Gehalt der Fibroblasten nicht signifikant gegenüber den Antisense-(Ad5TA2)-transduzierten Fibroblasten. In der modifizierten Boyden-Kammer wurde der AT2-vermittelte Effekt von Ang II, hPDGF-BB sowie der Kombination beider Stoffe auf die Migration untersucht. Die alleinige Stimulation von AT2-Rezeptoren mit Ang II verhinderte die Migration gegenüber nichttransduzierten Fibroblasten. In Kombination mit hPDGF-BB änderte Ang II die Migration in AT2-überexprimierenden Fibroblasten nicht gegenüber den Antisense-(Ad5TA2)-transduzierten Fibroblasten. Bei ausschließlicher Stimulation durch hPDGF-BB wurde aber in AT2-exprimierenden Fibroblasten eine signifikant geringere Migration als in Antisense-(Ad5TA2)-transduzierten Fibroblasten festgestellt. Die zugrunde liegende Hypothese, dass AT2-Expression und Stimulation den relativen Collagen I alpha 2-mRNA-Gehalt hemmt, konnte in den vorliegenden Experimenten nicht bestätigt werden. Dies ließ keine inhibitorische AT2-vermittelte Wirkung von Ang II im Bezug auf den TGF-beta1-induzierten Collagen I alpha 2-mRNA-Gehalt erkennen. Dagegen führte die Ang II-Stimulation überexprimierter AT2-Rezeptoren zu einer verringerten Migration und vermittelte so einen AT1-antagonistischen Effekt. / In this work the influence of expression and stimulation of the human AT2 receptor on Collagen I alpha 2-mRNA-content and migration of porcine cardiac fibroblastst was tested to clarify the question if AT2 receptors promote AT1 antagonistic antifibrotic and antimigratory effects on collagen I alpha 2-mRNA content and migration. To examine the AT2 receptor function in the cell culture AT2 cDNA was transferred into fibroblasts by adenoviral transduction and the AT2 receptor was overexpressed. Through the use of RT-PCR the relative changes in collagen I alpha 2-mRNA content in TGF-beta1 stimulated and TGF-beta1 plus Ang II stimulated fibroblasts were assayed and compared to the unstimulated control. All values were referred to a reference gene (beta-actin). Stimulation of AT2 receptors did not change the relative collagen I alpha 2-mRNA content of the fibroblasts significantly compared to antisense-(Ad5TA2) transduced fibroblasts. In the modified Boyden-chamber the AT2 mediated effect of Ang II, hPDGF-BB and the combination of both on migration was assessed. The stimulation of AT2 receptors with Ang II inhibited migration compared to nontransduced fibroblasts. In combination with hPDGF-BB Ang II did not change the migration in AT2 overexpressing fibroblasts compared to antisense-(Ad5TA2)-transduced fibroblasts. In the case of exclusive stimulation of AT2-expressing fibroblasts with hPDGF-BB a significantly lower migration was found compared to antisense-(Ad5TA2)-transduced fibroblasts. The underlying therory that AT2 expression and stimulation inhibits the relative collagen I alpha 2-mRNA content could not be confirmed in this work. This did not reveal an inhibitory AT2 mediated effect of Ang II in respect to the TGF-beta1 induced collagen I alpha 2-mRNA content. In contrast to that Ang II stimulation of overexpressed AT2 receptors led to a decreased migration and mediated an AT1 antagonistic effect.

A hipótese do estudo é a de que a Angiotensina II (AngII) é capaz de desencadear processos inflamatórios iniciais que compõem parte dos mecanismos envolvidos na lesão vascular ou no seu progresso. Os objetivos foram avaliar a expressão de marcadores iniciais de inflamação em resposta à ação da AngII e por qual receptor (AT1 ou AT2) esta levaria à expressão destes marcadores inflamatórios. O estudo foi realizado em camundongos machos C57Bl/6J submetidos ao tratamento com doses subpressoras de AngII, bloqueadores dos receptores AT1 e AT2 e uma combinação destes. Os tempos de tratamento foram determinados através de uma curva de tempo-resposta feita com injeções de AngII. Após definição da curva temporal foram preparados 6 grupos de animais: controle, tratados AngII, Losartan, AngII+Losartan, PD123319 e AngII+PD123319. Foram feitas avaliações dos marcadores inflamatórios nos corações por imunohistoquímica para citocinas IL-1<font face=\"Symbol\">b e IL-6, TNF<font face=\"Symbol\">a, TGF-<font face=\"Symbol\">b e MCP-1, a molécula de adesão ICAM-1, e foram quantificados a IL-6 e o TNF-<font face=\"Symbol\">a séricos pela técnica ELISA. / The study hypothesis is that the angiotensin II (Ang II) is capable of triggering inflammatory processes that comprise the initial part of the mechanisms involved in vascular injury or in progress. The objectives were to evaluate the expression of early markers of inflammation in response to the action of Ang II and which receptor (AT1 and AT2) this would lead to the expression of these inflammatory markers. The study was conducted in male C57Bl/6J mice undergoing treatment with subpressor doses of AngII, blockers of AT1 and AT2 receptors and a combination thereof. Treatment times were determined using a time-response curve performed with injections of AngII. After definition of time curve were prepared six animal groups: control, treated Ang II, losartan, Ang II + losartan, PD123319 and Ang II + PD123319. Evaluations were made in the hearts of inflammatory markers by immunohistochemistry for IL-1<font face=\"Symbol\">b and IL-6, TNF<font face=\"Symbol\">a, TGF-<font face=\"Symbol\">b and MCP-1, the adhesion TNF-<font face=\"Symbol\">a serum by ELISA.